Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505.SS)
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 834 | 1,140 | 1,031 | 851 | 709 | 686 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 165 | 213 | 138 | 109 | 40 | -157 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its associated entities, specializes in the research, development, production, and commercialization of cutting-edge biopharmaceutical products. The company's extensive pipeline is built upon several advanced technological platforms. Its genetic engineering platform prominently features antibody-drug conjugates (ADCs), with candidates like CD30-DM1 ADC and Trop2-SN38 ADC currently undergoing Phase I clinical trials for a range of tumors, including triple-negative breast, bladder, and gastric cancers. Additional ADCs, such as Trop2-BB05 (targeting lung cancer and triple-negative breast cancer) and HER2 ADC (for metastatic breast and gastric cancers), are in pre-clinical development or have completed pre-clinical research. Utilizing its photodynamic technical platform, the company provides hemoporfin, now in Phase IV clinical trials for the treatment of port wine stain. Another key product, aminolevulinic acid, is in Phase II trials for HPV-related cervical diseases and acne, having also completed pre-clinical studies for brain gliomas. Furthermore, Fudan-Zhangjiang employs nanotechnology in its drug development efforts. This includes Nanoparticle Albumin-bound Paclitaxel, which is in pre-clinical studies for various tumors, and a Doxorubicin liposome formulation also under development for oncology applications. The company's oral solid preparation technology platform has yielded obeticholic acid for hepatobiliary and autoimmune diseases. Other developments include timolol maleate cream, in pre-clinical studies for infantile hemangioma, and the FZJ-003 oral preparation, which is in Phase I for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond its core pharmaceutical development, the company is involved in creating pharmaceutical and medical devices, offering medical diagnostic products and related services, and distributing daily necessities, along with clinical laboratory analysis instruments and software. Its activities also encompass technology development, transfer, consulting, and promotion, the manufacture of freeze-dried powder injections and active pharmaceutical ingredients (APIs), and investments in international medical projects. Established in 1996, the company is based in Shanghai, People's Republic of China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505.SS)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its associated entities, specializes in the research, development, production, and commercialization of cutting-edge biopharmaceutical products. The company's extensive pipeline is built upon several advanced technological platforms. Its genetic engineering platform prominently features antibody-drug conjugates (ADCs), with candidates like CD30-DM1 ADC and Trop2-SN38 ADC currently undergoing Phase I clinical trials for a range of tumors, including triple-negative breast, bladder, and gastric cancers. Additional ADCs, such as Trop2-BB05 (targeting lung cancer and triple-negative breast cancer) and HER2 ADC (for metastatic breast and gastric cancers), are in pre-clinical development or have completed pre-clinical research. Utilizing its photodynamic technical platform, the company provides hemoporfin, now in Phase IV clinical trials for the treatment of port wine stain. Another key product, aminolevulinic acid, is in Phase II trials for HPV-related cervical diseases and acne, having also completed pre-clinical studies for brain gliomas. Furthermore, Fudan-Zhangjiang employs nanotechnology in its drug development efforts. This includes Nanoparticle Albumin-bound Paclitaxel, which is in pre-clinical studies for various tumors, and a Doxorubicin liposome formulation also under development for oncology applications. The company's oral solid preparation technology platform has yielded obeticholic acid for hepatobiliary and autoimmune diseases. Other developments include timolol maleate cream, in pre-clinical studies for infantile hemangioma, and the FZJ-003 oral preparation, which is in Phase I for rheumatoid arthritis and Phase II for atopic dermatitis and ulcerative colitis. Beyond its core pharmaceutical development, the company is involved in creating pharmaceutical and medical devices, offering medical diagnostic products and related services, and distributing daily necessities, along with clinical laboratory analysis instruments and software. Its activities also encompass technology development, transfer, consulting, and promotion, the manufacture of freeze-dried powder injections and active pharmaceutical ingredients (APIs), and investments in international medical projects. Established in 1996, the company is based in Shanghai, People's Republic of China.